Brief: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
03/06/2025 21:24
June 3 (Reuters) - AnaptysBio Inc ANAB.O: ANAPTYS ANNOUNCES POSITIVE ROSNILIMAB DATA UPDATED THROUGH SIX MONTHS IN ROBUST PHASE 2B TRIAL IN RA Source text: ID:nGNXH0WLB Further company coverage: ANAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties